Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Accumulated Depreciation (2017 - 2025)

Crinetics Pharmaceuticals has reported Accumulated Depreciation over the past 9 years, most recently at $9.6 million for Q2 2025.

  • For Q2 2025, Accumulated Depreciation rose 53.84% year-over-year to $9.6 million; the TTM value through Jun 2025 reached $9.6 million, up 53.84%, while the annual FY2024 figure was $7.7 million, 52.57% up from the prior year.
  • Accumulated Depreciation for Q2 2025 was $9.6 million at Crinetics Pharmaceuticals, up from $8.6 million in the prior quarter.
  • Over five years, Accumulated Depreciation peaked at $9.6 million in Q2 2025 and troughed at $3.0 million in Q1 2021.
  • A 5-year average of $5.2 million and a median of $4.6 million in 2023 define the central range for Accumulated Depreciation.
  • Biggest five-year swings in Accumulated Depreciation: skyrocketed 62.02% in 2021 and later grew 16.95% in 2023.
  • Year by year, Accumulated Depreciation stood at $3.5 million in 2021, then rose by 17.36% to $4.1 million in 2022, then increased by 24.09% to $5.1 million in 2023, then soared by 52.57% to $7.7 million in 2024, then increased by 23.98% to $9.6 million in 2025.
  • Business Quant data shows Accumulated Depreciation for CRNX at $9.6 million in Q2 2025, $8.6 million in Q1 2025, and $7.7 million in Q4 2024.